These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12727976)

  • 21. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment.
    Festen DA; de Weerd AW; van den Bossche RA; Joosten K; Hoeve H; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4911-5. PubMed ID: 17003096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome.
    Haqq AM; Stadler DD; Rosenfeld RG; Pratt KL; Weigle DS; Frayo RS; LaFranchi SH; Cummings DE; Purnell JQ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3573-6. PubMed ID: 12915638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome.
    Miller J; Silverstein J; Shuster J; Driscoll DJ; Wagner M
    J Clin Endocrinol Metab; 2006 Feb; 91(2):413-7. PubMed ID: 16317059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome.
    Eiholzer U; Weber R; Stutz K; Steinert H
    Acta Paediatr Suppl; 1997 Nov; 423():66-8. PubMed ID: 9401543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
    Fillion M; Deal C; Van Vliet G
    J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
    Carrel AL; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.
    Eiholzer U; l'Allemand D; van der Sluis I; Steinert H; Gasser T; Ellis K
    Horm Res; 2000; 53(4):200-6. PubMed ID: 11044804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C; Hilding A; Jacobsson H; Thorén M
    Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome.
    Sipilä I; Sintonen H; Hietanen H; Apajasalo M; Alanne S; Viita AM; Leinonen E
    Acta Paediatr; 2010 Nov; 99(11):1712-8. PubMed ID: 20545932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study.
    Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Troeman ZC; van Alfen-van der Velden AA; Otten BJ; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Oostdijk W; Bocca G; Mieke Houdijk EC; van Trotsenburg AS; Hoorweg-Nijman JJ; van Wieringen H; Vreuls RC; Jira PE; Schroor EJ; van Pinxteren-Nagler E; Willem Pilon J; Lunshof LB; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2307-14. PubMed ID: 22508707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
    Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome.
    Davies PS; Evans S; Broomhead S; Clough H; Day JM; Laidlaw A; Barnes ND
    Arch Dis Child; 1998 May; 78(5):474-6. PubMed ID: 9659098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months.
    Whitman B; Carrel A; Bekx T; Weber C; Allen D; Myers S
    J Pediatr Endocrinol Metab; 2004 Apr; 17(4):591-600. PubMed ID: 15198290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
    Acta Paediatr Suppl; 1997 Nov; 423():60-2. PubMed ID: 9401542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.